Oncology, respiratory diseases and diabetes all have diverse patient populations who receive multiple lines of therapy involving many different combinations of drugs and drug classes. The difficulty of the forecasting task is magnified further with the selection of subsequent lines of therapy often depending on how the patient responded to previous therapies. Information that fails to consider these complexities will not only be inadequate, but worse may be very misleading.
- Learn about the benefits of simulation over allocation in forecasting
- Understand how to incorporate patient and treatment complexity into forecasting models
- Gain perspective on how to incorporate future products/indications into these complex models